Literature DB >> 10784585

Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis.

M Honda1, F Orii, T Ayabe, S Imai, T Ashida, T Obara, Y Kohgo.   

Abstract

BACKGROUND & AIMS: Recently, the glucocorticoid receptor beta (hGRbeta) was suggested to play a role as a dominant negative regulator for determining glucocorticoid response. The aim of this study was to clarify whether reverse-transcription polymerase chain reaction (RT-PCR) analysis of hGRbeta messenger RNA (mRNA) can predict the response to glucocorticoids in patients with ulcerative colitis.
METHODS: Total RNA obtained from peripheral blood mononuclear cells (PBMCs) of 23 patients with ulcerative colitis and 20 healthy volunteers was reverse transcribed; the resulting complementary DNA was amplified using specific primers for hGRalpha and hGRbeta. Protein expression of hGR in PBMCs was confirmed by immunoprecipitation-Western blot analysis.
RESULTS: The expression of hGRalpha mRNA (477 base pairs) was detected in all patients and all healthy volunteers. In contrast, a hGRbeta mRNA (366 base pairs) was detected in 1 (9.1%) of 11 glucocorticoid-sensitive patients, 10 (83.3%) of 12 glucocorticoid-resistant patients, and 2 (10%) of 20 healthy volunteers. The positive rate of hGRbeta mRNA in the resistant group was significantly higher than that in the sensitive group (P = 0.0019). The hGRbeta band could be detected by immunoprecipitation-Western blotting in hGRbeta mRNA-positive patients.
CONCLUSIONS: The results show that the expression of hGRbeta mRNA in PBMCs examined by RT-PCR may serve as a novel predictor of glucocorticoid response in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10784585     DOI: 10.1016/s0016-5085(00)70172-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  61 in total

Review 1.  Clinical pharmacology of inflammatory bowel disease therapies.

Authors:  W J Sandborn; W A Faubion
Journal:  Curr Gastroenterol Rep       Date:  2000-12

2.  Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus.

Authors:  Rosangela Soares Chriguer; Ana Maria Roselino; Margaret de Castro
Journal:  J Clin Immunol       Date:  2012-03-10       Impact factor: 8.317

3.  Molecular origins for the dominant negative function of human glucocorticoid receptor beta.

Authors:  Matthew R Yudt; Christine M Jewell; Rachelle J Bienstock; John A Cidlowski
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

4.  Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Authors:  Maria T. Abreu
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

5.  Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active.

Authors:  Laura J Lewis-Tuffin; Christine M Jewell; Rachelle J Bienstock; Jennifer B Collins; John A Cidlowski
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

6.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 7.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

Review 8.  The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease.

Authors:  A Sasha Tait; Cherie L Butts; Esther M Sternberg
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

Review 9.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Production of inflammatory mediators by renal epithelial cells is insensitive to glucocorticoids.

Authors:  Simone de Haij; Andrea M Woltman; Astrid C Bakker; Mohamed R Daha; Cees van Kooten
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.